Fig. 3: Bivalent non-recipients exhibit stronger boosting of variant-neutralizing and spike RBD-binding isotype titers. | Communications Medicine

Fig. 3: Bivalent non-recipients exhibit stronger boosting of variant-neutralizing and spike RBD-binding isotype titers.

From: Immune imprinting and vaccine interval determine antibody responses to monovalent XBB.1.5 COVID-19 vaccination

Fig. 3

Live SARS-CoV-2 neutralizing antibodies were quantified by focus reduction neutralization test (FRNT) and reported as FRNT50s. Fold changes were calculated by dividing the post-XBB.1.5 vaccination titer by pre-vaccination titer for each participant against WA1 (a), XBB.1.5 (b), EG.5.1 (c), and JN.1 (d). Ancestral spike RBD-binding antibodies were determined by enzyme-linked immunosorbent assay (ELISA) and reported as EC50s. Fold-changes were calculated for IgG (e), IgA (f), IgM (g), and total IgG/A/M (h). The dotted lines indicate no change in titer from pre- to post-vaccination (fold change = 1). Error bars show geometric means with 95% confidence intervals. Reported p-values are the result of unpaired t tests between bivalent recipients (n = 30) and non-recipients (n = 10).

Back to article page